Literature DB >> 18537971

CD39 is incorporated into plasma microparticles where it maintains functional properties and impacts endothelial activation.

Yara Banz1, Guido Beldi, Yan Wu, Ben Atkinson, Anny Usheva, Simon C Robson.   

Abstract

Plasma microparticles (MPs, <1.5 mum) originate from platelet and cell membrane lipid rafts and possibly regulate inflammatory responses and thrombogenesis. These actions are mediated through their phospholipid-rich surfaces and associated cell-derived surface molecules. The ectonucleotidase CD39/ecto-nucleoside triphosphate diphosphohydrolase1 (E-NTPDase1) modulates purinergic signalling through pericellular ATP and ADP phosphohydrolysis and is localized within lipid rafts in the membranes of endothelial- and immune cells. This study aimed to determine whether CD39 associates with circulating MPs and might further impact phenotype and function. Plasma MPs were found to express CD39 and exhibited classic E-NTPDase ecto-enzymatic activity. Entpd1 (Cd39) deletion in mice produced a pro-inflammatory phenotype associated with quantitative and qualitative differences in the MP populations, as determined by two dimensional-gel electrophoresis, western blot and flow cytometry. Entpd1-null MPs were also more abundant, had significantly higher proportions of platelet- and endothelial-derived elements and decreased levels of interleukin-10, tumour necrosis factor receptor 1 and matrix metalloproteinase 2. Consequently, Cd39-null MP augment endothelial activation, as determined by inflammatory cytokine release and upregulation of adhesion molecules in vitro. In conclusion, CD39 associates with circulating MP and may directly or indirectly confer functional properties. Our data also suggest a modulatory role for CD39 within MP in the exchange of regulatory signals between leucocytes and vascular cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18537971      PMCID: PMC2886720          DOI: 10.1111/j.1365-2141.2008.07230.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  45 in total

1.  Endothelial cell activation by leukocyte microparticles.

Authors:  M Mesri; D C Altieri
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

2.  Cellular origin and procoagulant properties of microparticles in meningococcal sepsis.

Authors:  R Nieuwland; R J Berckmans; S McGregor; A N Böing; F P Romijn; R G Westendorp; C E Hack; A Sturk
Journal:  Blood       Date:  2000-02-01       Impact factor: 22.113

3.  Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation.

Authors:  K Enjyoji; J Sévigny; Y Lin; P S Frenette; P D Christie; J S Esch; M Imai; J M Edelberg; H Rayburn; M Lech; D L Beeler; E Csizmadia; D D Wagner; S C Robson; R D Rosenberg
Journal:  Nat Med       Date:  1999-09       Impact factor: 53.440

4.  CD39 is the dominant Langerhans cell-associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness.

Authors:  Norikatsu Mizumoto; Tadashi Kumamoto; Simon C Robson; Jean Sévigny; Hiroyuki Matsue; Keiichi Enjyoji; Akira Takashima
Journal:  Nat Med       Date:  2002-04       Impact factor: 53.440

Review 5.  Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation.

Authors:  Simon C Robson; Yan Wu; Xiaofeng Sun; Christoph Knosalla; Karen Dwyer; Keiichi Enjyoji
Journal:  Semin Thromb Hemost       Date:  2005-04       Impact factor: 4.180

6.  Adenovirus-mediated transfer of human placental ectonucleoside triphosphate diphosphohydrolase to vascular smooth muscle cells suppresses platelet aggregation in vitro and arterial thrombus formation in vivo.

Authors:  Eiji Furukoji; Masanori Matsumoto; Atsushi Yamashita; Hideo Yagi; Yoshihiko Sakurai; Kousuke Marutsuka; Kinta Hatakeyama; Kazuhiro Morishita; Yoshihiro Fujimura; Shozo Tamura; Yujiro Asada
Journal:  Circulation       Date:  2005-02-07       Impact factor: 29.690

7.  CD39/NTPDase-1 activity and expression in normal leukocytes.

Authors:  E Dianne Pulte; M Johan Broekman; Kim E Olson; Joan H F Drosopoulos; Jorge R Kizer; Naziba Islam; Aaron J Marcus
Journal:  Thromb Res       Date:  2007-06-07       Impact factor: 3.944

8.  Specificity of the ecto-ATPase inhibitor ARL 67156 on human and mouse ectonucleotidases.

Authors:  S A Lévesque; E G Lavoie; J Lecka; F Bigonnesse; J Sévigny
Journal:  Br J Pharmacol       Date:  2007-07-02       Impact factor: 8.739

9.  Monocyte vesiculation is a possible mechanism for dissemination of membrane-associated procoagulant activities and adhesion molecules after stimulation by lipopolysaccharide.

Authors:  N Satta; F Toti; O Feugeas; A Bohbot; J Dachary-Prigent; V Eschwège; H Hedman; J M Freyssinet
Journal:  J Immunol       Date:  1994-10-01       Impact factor: 5.422

10.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

View more
  23 in total

Review 1.  Which anti-platelet therapies might be beneficial in xenotransplantation?

Authors:  Moritz Schmelzle; Peter J Cowan; Simon C Robson
Journal:  Xenotransplantation       Date:  2011 Mar-Apr       Impact factor: 3.907

Review 2.  The CD39-adenosinergic axis in the pathogenesis of renal ischemia-reperfusion injury.

Authors:  Veena Roberts; Bo Lu; Siddharth Rajakumar; Peter J Cowan; Karen M Dwyer
Journal:  Purinergic Signal       Date:  2012-11-29       Impact factor: 3.765

3.  Role of the CD39/CD73 Purinergic Pathway in Modulating Arterial Thrombosis in Mice.

Authors:  Roman Covarrubias; Elena Chepurko; Adam Reynolds; Zachary M Huttinger; Ryan Huttinger; Katherine Stanfill; Debra G Wheeler; Tatiana Novitskaya; Simon C Robson; Karen M Dwyer; Peter J Cowan; Richard J Gumina
Journal:  Arterioscler Thromb Vasc Biol       Date:  2016-07-14       Impact factor: 8.311

4.  Novel therapeutic concepts for inflammatory bowel disease-from bench to bedside.

Authors:  Viola Neudecker; Sean P Colgan; Holger K Eltzschig
Journal:  J Mol Med (Berl)       Date:  2017-09       Impact factor: 4.599

5.  CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice.

Authors:  Xiaofeng Sun; Yan Wu; Wenda Gao; Keiichi Enjyoji; Eva Csizmadia; Christa E Müller; Takashi Murakami; Simon C Robson
Journal:  Gastroenterology       Date:  2010-06-25       Impact factor: 22.682

6.  Increased plasma levels of microparticles expressing CD39 and CD133 in acute liver injury.

Authors:  Moritz Schmelzle; Katrin Splith; Lars W Andersen; Miroslaw Kornek; Detlef Schuppan; Caitlin Jones-Bamman; Martina Nowak; Vasilis Toxavidis; Steven D Salhanick; Lihui Han; Jan Schulte am Esch; Sven Jonas; Michael W Donnino; Simon C Robson
Journal:  Transplantation       Date:  2013-01-15       Impact factor: 4.939

Review 7.  Cellular function and molecular structure of ecto-nucleotidases.

Authors:  Herbert Zimmermann; Matthias Zebisch; Norbert Sträter
Journal:  Purinergic Signal       Date:  2012-05-04       Impact factor: 3.765

8.  Metabolism of circulating ADP in the bloodstream is mediated via integrated actions of soluble adenylate kinase-1 and NTPDase1/CD39 activities.

Authors:  Gennady G Yegutkin; Bé Wieringa; Simon C Robson; Sirpa Jalkanen
Journal:  FASEB J       Date:  2012-05-25       Impact factor: 5.191

9.  Delayed targeting of CD39 to activated platelet GPIIb/IIIa via a single-chain antibody: breaking the link between antithrombotic potency and bleeding?

Authors:  Jan David Hohmann; Xiaowei Wang; Stefanie Krajewski; Carly Selan; Carolyn A Haller; Andreas Straub; Elliot L Chaikof; Harshal H Nandurkar; Christoph E Hagemeyer; Karlheinz Peter
Journal:  Blood       Date:  2013-02-04       Impact factor: 22.113

10.  Characterization of circulating microparticle-associated CD39 family ecto-nucleotidases in human plasma.

Authors:  Z Gordon Jiang; Yan Wu; Eva Csizmadia; Linda Feldbrügge; Keiichi Enjyoji; John Tigges; Vasilis Toxavidis; Holger Stephan; Christa E Müller; Christina E Müller; C James McKnight; Alan Moss; Simon C Robson
Journal:  Purinergic Signal       Date:  2014-08-28       Impact factor: 3.765

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.